JP2017537165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537165A5 JP2017537165A5 JP2017548369A JP2017548369A JP2017537165A5 JP 2017537165 A5 JP2017537165 A5 JP 2017537165A5 JP 2017548369 A JP2017548369 A JP 2017548369A JP 2017548369 A JP2017548369 A JP 2017548369A JP 2017537165 A5 JP2017537165 A5 JP 2017537165A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- max
- target
- solabegron
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LLDXOPKUNJTIRF-QFIPXVFZSA-N solabegron Chemical compound C([C@H](O)C=1C=C(Cl)C=CC=1)NCCNC(C=1)=CC=CC=1C1=CC=CC(C(O)=O)=C1 LLDXOPKUNJTIRF-QFIPXVFZSA-N 0.000 claims description 19
- 229950009659 solabegron Drugs 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 10
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 87
- 238000011282 treatment Methods 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 5
- 230000036506 anxiety Effects 0.000 claims 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 4
- 108030001720 Bontoxilysin Proteins 0.000 claims 4
- 229930003827 cannabinoid Natural products 0.000 claims 4
- 239000003557 cannabinoid Substances 0.000 claims 4
- 238000012377 drug delivery Methods 0.000 claims 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 4
- 239000003149 muscarinic antagonist Substances 0.000 claims 4
- 230000007383 nerve stimulation Effects 0.000 claims 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 4
- 150000003180 prostaglandins Chemical class 0.000 claims 4
- 239000012268 protein inhibitor Substances 0.000 claims 4
- 229940121649 protein inhibitor Drugs 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 210000002972 tibial nerve Anatomy 0.000 claims 4
- 230000001052 transient effect Effects 0.000 claims 4
- 206010020853 Hypertonic bladder Diseases 0.000 claims 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 3
- 208000005107 Premature Birth Diseases 0.000 claims 3
- 206010036590 Premature baby Diseases 0.000 claims 3
- 229940053031 botulinum toxin Drugs 0.000 claims 3
- 229940065144 cannabinoids Drugs 0.000 claims 3
- 208000020629 overactive bladder Diseases 0.000 claims 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 3
- 108010084938 adenovirus receptor Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000001022 anti-muscarinic effect Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000027939 micturition Effects 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 208000017497 prostate disease Diseases 0.000 claims 2
- 239000003422 purinergic receptor affecting agent Substances 0.000 claims 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010029446 nocturia Diseases 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087021P | 2014-12-03 | 2014-12-03 | |
| US62/087,021 | 2014-12-03 | ||
| PCT/US2015/063795 WO2016090168A1 (en) | 2014-12-03 | 2015-12-03 | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537165A JP2017537165A (ja) | 2017-12-14 |
| JP2017537165A5 true JP2017537165A5 (enExample) | 2019-01-10 |
Family
ID=56092482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548369A Ceased JP2017537165A (ja) | 2014-12-03 | 2015-12-03 | 下部尿路系症状を対象とした徐放性ソラベグロンの組成物及び使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9956194B2 (enExample) |
| EP (1) | EP3226849A4 (enExample) |
| JP (1) | JP2017537165A (enExample) |
| KR (1) | KR20170086659A (enExample) |
| CN (1) | CN107205964A (enExample) |
| AU (1) | AU2015358378A1 (enExample) |
| CA (1) | CA2969405A1 (enExample) |
| EA (1) | EA201791225A1 (enExample) |
| HK (1) | HK1245117A1 (enExample) |
| IL (1) | IL252628A0 (enExample) |
| MX (1) | MX2017007054A (enExample) |
| WO (1) | WO2016090168A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| HK1245117A1 (zh) | 2014-12-03 | 2018-08-24 | Velicept Therapeutics, Inc. | 使用调节释放索拉贝隆用於下尿路症状的组合物和方法 |
| ES2967863T3 (es) * | 2015-10-23 | 2024-05-06 | B3Ar Therapeutics Inc | Ion dipolar de solabegron y usos del mismo |
| EP3463307A4 (en) * | 2016-06-03 | 2020-01-15 | Velicept Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| EP3634420A1 (en) | 2017-06-06 | 2020-04-15 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| SG11202103662VA (en) | 2018-12-05 | 2021-06-29 | Urovant Sciences Gmbh | Vibegron for the treatment of overactive bladder symptoms |
| EP4313019A4 (en) * | 2021-03-31 | 2025-02-12 | B3AR Therapeutics, Inc. | Compositions of micronized solabegron and methods of use |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL124473C (enExample) | 1960-07-26 | |||
| DE2965655D1 (en) | 1978-06-28 | 1983-07-21 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
| GB8519154D0 (en) | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
| JPH0236571B2 (ja) * | 1986-04-11 | 1990-08-17 | Otsuka Pharma Co Ltd | Jizokuseiseizai |
| DE3934436A1 (de) | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5061727A (en) | 1990-05-04 | 1991-10-29 | American Cyanamid Company | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles |
| NO179246C (no) | 1991-11-20 | 1996-09-04 | Sankyo Co | Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav |
| WO1995033724A1 (en) | 1994-06-09 | 1995-12-14 | Glaxo Group Limited | Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists |
| US5677346A (en) | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| WO1997015549A1 (en) | 1995-10-26 | 1997-05-01 | Tokyo Tanabe Company Limited | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME |
| US6123961A (en) | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| MXPA01004381A (es) | 1998-11-02 | 2005-09-08 | Elan Corp Plc | Composicion de multiparticulado de liberacion modificada. |
| US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| GB9929297D0 (en) | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
| US20030018061A1 (en) | 2000-01-28 | 2003-01-23 | Kohei Ogawa | Novel remedies with the use of beta 3 agonist |
| US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6444685B1 (en) | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
| US6395762B1 (en) | 2000-07-17 | 2002-05-28 | American Home Products Corporation | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
| US7034053B2 (en) | 2001-01-31 | 2006-04-25 | Smithkline Beecham Corporation | Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors |
| GB0102407D0 (en) | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
| US7709677B2 (en) | 2001-01-31 | 2010-05-04 | Glaxosmithkline Llc | Process of preparing arylethanoldiamines |
| AP1748A (en) * | 2001-03-13 | 2007-06-11 | Penwest Pharmaceuticals Co | Chronotherapeutic dosage forms. |
| WO2003024483A1 (fr) | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
| TWI295669B (en) | 2002-10-30 | 2008-04-11 | Theravance Inc | Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds |
| EP1424079A1 (en) | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| WO2005042021A2 (de) | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer |
| DE10352132A1 (de) | 2003-11-04 | 2005-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten |
| DE602004021847D1 (de) | 2003-11-27 | 2009-08-13 | Develogen Ag | Verfahren zur prävention und behandlung von diabetes mit neurturin |
| AU2004312059A1 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
| EP1550447A1 (en) | 2004-01-02 | 2005-07-06 | Schering Aktiengesellschaft | Menstrual cycle control and improvement of conception rates in females |
| WO2005077364A1 (ja) | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | ソリフェナシンの経皮投与製剤およびその経皮透過改善方法 |
| CA2580170A1 (en) | 2004-10-18 | 2006-04-27 | Boehringer Ingelheim International Gmbh | Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract |
| EP1871347B1 (en) | 2005-04-19 | 2016-08-03 | Novartis AG | Pharmaceutical composition |
| CN101242813A (zh) * | 2005-06-20 | 2008-08-13 | 依兰药物国际有限公司 | 包含芳基-杂环化合物的毫微粒和控制释放组合物 |
| EP1769792A1 (de) | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
| ITMI20061581A1 (it) | 2006-08-04 | 2008-02-05 | Univ Bari | Ligandi del recettore beta-3 adrenergico e loro uso in terapia |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| AU2008233232A1 (en) | 2007-03-29 | 2008-10-09 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment-of lower urinary tract symptoms |
| GB0714790D0 (en) * | 2007-07-30 | 2007-09-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| CA2704298C (en) | 2007-11-02 | 2015-07-21 | Astellas Pharma Inc. | Pharmaceutical composition for treating overactive bladder |
| CA2719907A1 (en) | 2008-04-04 | 2009-10-08 | Merck Sharp & Dohme Corp. | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
| PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| EP2181707A1 (en) | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent |
| US8778998B2 (en) | 2009-04-10 | 2014-07-15 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| WO2010129326A1 (en) | 2009-05-08 | 2010-11-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-derived beta 3 adrenergic receptor agonists |
| US8586760B2 (en) | 2009-06-15 | 2013-11-19 | Auspex Pharmaceuticals, Inc. | Aminothiazole modulators of beta-3-adrenoreceptor |
| MX2012002366A (es) | 2009-08-27 | 2012-03-29 | Merck Sharp & Dohme | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. |
| US8354403B2 (en) | 2009-08-27 | 2013-01-15 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
| WO2011043942A1 (en) | 2009-10-07 | 2011-04-14 | Merck Sharp & Dohme Corp. | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
| WO2011137054A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| WO2016004056A1 (en) | 2014-07-03 | 2016-01-07 | Velicept Therapeutics, Inc. | Pharmaceutical combinations |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| AU2011285928B9 (en) * | 2010-08-03 | 2018-08-02 | B3Ar Therapeutics, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| US20120289560A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
| TW201338772A (zh) | 2012-02-09 | 2013-10-01 | Altherx Inc | 藥學組合物 |
| CA2883270A1 (en) | 2012-08-31 | 2014-03-06 | Astellas Pharma Inc. | Orally administered medical composition |
| US20150306170A1 (en) | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
| EP2961730A2 (en) | 2013-02-26 | 2016-01-06 | XenoPort, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
| JPWO2014171542A1 (ja) * | 2013-04-19 | 2017-02-23 | 武田薬品工業株式会社 | 放出制御製剤 |
| CN105579057A (zh) | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| KR20160117596A (ko) | 2014-02-07 | 2016-10-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 신규 제약 제제 |
| JP2017078023A (ja) | 2014-02-28 | 2017-04-27 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| HK1245117A1 (zh) | 2014-12-03 | 2018-08-24 | Velicept Therapeutics, Inc. | 使用调节释放索拉贝隆用於下尿路症状的组合物和方法 |
| ES2967863T3 (es) | 2015-10-23 | 2024-05-06 | B3Ar Therapeutics Inc | Ion dipolar de solabegron y usos del mismo |
| US10543174B2 (en) | 2016-04-25 | 2020-01-28 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| EP3463307A4 (en) | 2016-06-03 | 2020-01-15 | Velicept Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS |
| US20170348288A1 (en) | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder |
-
2015
- 2015-12-03 HK HK18104631.7A patent/HK1245117A1/zh unknown
- 2015-12-03 CN CN201580074649.0A patent/CN107205964A/zh active Pending
- 2015-12-03 CA CA2969405A patent/CA2969405A1/en not_active Abandoned
- 2015-12-03 EA EA201791225A patent/EA201791225A1/ru unknown
- 2015-12-03 JP JP2017548369A patent/JP2017537165A/ja not_active Ceased
- 2015-12-03 EP EP15865588.6A patent/EP3226849A4/en not_active Withdrawn
- 2015-12-03 US US14/958,610 patent/US9956194B2/en active Active
- 2015-12-03 WO PCT/US2015/063795 patent/WO2016090168A1/en not_active Ceased
- 2015-12-03 AU AU2015358378A patent/AU2015358378A1/en not_active Abandoned
- 2015-12-03 KR KR1020177018393A patent/KR20170086659A/ko not_active Withdrawn
- 2015-12-03 MX MX2017007054A patent/MX2017007054A/es unknown
-
2017
- 2017-06-01 IL IL252628A patent/IL252628A0/en unknown
-
2018
- 2018-04-12 US US15/951,968 patent/US10751311B2/en active Active
- 2018-04-12 US US15/951,953 patent/US20190083433A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537165A5 (enExample) | ||
| Zhou et al. | Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β | |
| Yamawaki et al. | Nrf2 activator for the treatment of kidney diseases | |
| JP2026027257A (ja) | うつ病の治療のためのエスケタミン | |
| EP3038654B1 (en) | New use | |
| US20220000824A1 (en) | Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid | |
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| Karuppagounder et al. | Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFκB p65 mediated inflammation | |
| CN112512633A (zh) | 使用gip/glp1共激动剂用于治疗的方法 | |
| Scott | Linagliptin: in type 2 diabetes mellitus | |
| JP6957455B2 (ja) | ベータ細胞の複製及び／または生存の亢進 | |
| Khan et al. | Current updates in the medical management of obesity | |
| WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| EP3463307A1 (en) | Compositions and methods of using modified release solabegron for lower urinary tract symptoms | |
| EP3518936B1 (en) | Pharmaceutical composition for treatment of non-alcoholic fatty liver disease | |
| Abdul-Rahman et al. | The power of three: Retatrutide's role in modern obesity and diabetes therapy | |
| Preston et al. | Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study | |
| Yao et al. | Ganoderma lucidum polysaccharide ameliorated diabetes mellitus-induced erectile dysfunction in rats by regulating fibrosis and the NOS/ERK/JNK pathway | |
| AU2020201980A1 (en) | Combination of FXR agonists | |
| Tilinca et al. | THE NEWEST THERAPEUTICALLY APPROACH OF" DIABESITY" USING GLP-1 RA MOLECULES: IMPACT OF THE ORAL FORMULATION. | |
| AU2007280636B2 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| US9956182B2 (en) | Cannabidiol for the prevention and treatment of graft-versus-host disease | |
| Alhomoud et al. | Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems | |
| Sun et al. | Blockade of angiotensin II with losartan attenuates transforming growth factor-β1 inducible gene-h3 (βig-h3) expression in a model of chronic cyclosporine nephrotoxicity | |
| EP4000630B1 (en) | Incretin for elevated intracranial pressure treatment |